Is (+)-[13C]-pantoprazole better than (±)-[ 13C]-pantoprazole for the breath test to evaluate CYP2C19 enzyme activity?

David L. Thacker, Anil Modak, David A. Flockhart, Zeruesenay Desta

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Recently, we have shown that the (+)-[13C]-pantoprazole is more dependent on CYP2C19 metabolic status than (-)-[13C]-pantoprazole. In this study, we tested the hypothesis that (+)-[13C]-pantoprazole is a more sensitive and selective probe for evaluating CYP2C19 enzyme activity than the racemic mixture. (+)-[13C]-pantoprazole (95 mg) was administered orally in a sodium bicarbonate solution to healthy volunteers. Breath and plasma samples were collected before and up to 720 min after dosing. The 13CO2 in exhaled breath samples was measured by infrared spectrometry. Ratios of 13CO2/12CO2 after (+)-[13C]-pantoprazole relative to 13CO 2/12CO2 at baseline were expressed as delta over baseline (DOB). (+)-[13C]-pantoprazole concentrations were measured by HPLC. Genomic DNA extracted from whole blood was genotyped for CYP2C19*2, *3 and *17 using Taqman assays. Statistically significant differences in the area under the plasma concentration time curve (AUCplasma (0-∞) (p < 0.001) and oral clearance (<0.01) of (+)-[13C]-pantoprazole as well as in the breath test indices (delta over baseline, DOB30; and area under the DOB versus time curve, AUCDOB (0-120)) (p < 0.01) were observed among poor, intermediate and extensive metabolizer of CYP2C19. DOB30 and AUC DOB (0-120) adequately distinguished poor metabolizer from intermediate and extensive metabolizer of CYP2C19. Breath test indices significantly correlated with plasma elimination parameters of (+)-[ 13C]-pantoprazole (Pearson correlations: -0.68 to -0.73). Although relatively higher breath test indices were observed after administration of (+)-[13C]-pantoprazole (this study) than after (±)-[ 13C]-pantoprazole (previous study), the performance of the racemic and the enantiomer as marker of CYP2C19 activity remained similar. Our data confirm that the metabolism of (+)-[13C]-pantoprazole is highly dependent on CYP2C19 metabolic status, but the breath test derived from it is not superior to the racemic [13C]-pantoprazole in evaluating CYP2C19 activity in vivo. Thus, racemic [13C]-pantoprazole which is relatively easy to synthesize and more stable than (+)-[13C]- pantoprazole is adequate as a probe of this enzyme.

Original languageEnglish
Article number016001
JournalJournal of Breath Research
Volume7
Issue number1
DOIs
StatePublished - Mar 2013

Fingerprint

Breath Tests
Enzymes
pantoprazole
Cytochrome P-450 CYP2C19
Sodium Bicarbonate
Area Under Curve

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Is (+)-[13C]-pantoprazole better than (±)-[ 13C]-pantoprazole for the breath test to evaluate CYP2C19 enzyme activity? / Thacker, David L.; Modak, Anil; Flockhart, David A.; Desta, Zeruesenay.

In: Journal of Breath Research, Vol. 7, No. 1, 016001, 03.2013.

Research output: Contribution to journalArticle

@article{af6240649fa44820acfab7b57ff40a2e,
title = "Is (+)-[13C]-pantoprazole better than (±)-[ 13C]-pantoprazole for the breath test to evaluate CYP2C19 enzyme activity?",
abstract = "Recently, we have shown that the (+)-[13C]-pantoprazole is more dependent on CYP2C19 metabolic status than (-)-[13C]-pantoprazole. In this study, we tested the hypothesis that (+)-[13C]-pantoprazole is a more sensitive and selective probe for evaluating CYP2C19 enzyme activity than the racemic mixture. (+)-[13C]-pantoprazole (95 mg) was administered orally in a sodium bicarbonate solution to healthy volunteers. Breath and plasma samples were collected before and up to 720 min after dosing. The 13CO2 in exhaled breath samples was measured by infrared spectrometry. Ratios of 13CO2/12CO2 after (+)-[13C]-pantoprazole relative to 13CO 2/12CO2 at baseline were expressed as delta over baseline (DOB). (+)-[13C]-pantoprazole concentrations were measured by HPLC. Genomic DNA extracted from whole blood was genotyped for CYP2C19*2, *3 and *17 using Taqman assays. Statistically significant differences in the area under the plasma concentration time curve (AUCplasma (0-∞) (p < 0.001) and oral clearance (<0.01) of (+)-[13C]-pantoprazole as well as in the breath test indices (delta over baseline, DOB30; and area under the DOB versus time curve, AUCDOB (0-120)) (p < 0.01) were observed among poor, intermediate and extensive metabolizer of CYP2C19. DOB30 and AUC DOB (0-120) adequately distinguished poor metabolizer from intermediate and extensive metabolizer of CYP2C19. Breath test indices significantly correlated with plasma elimination parameters of (+)-[ 13C]-pantoprazole (Pearson correlations: -0.68 to -0.73). Although relatively higher breath test indices were observed after administration of (+)-[13C]-pantoprazole (this study) than after (±)-[ 13C]-pantoprazole (previous study), the performance of the racemic and the enantiomer as marker of CYP2C19 activity remained similar. Our data confirm that the metabolism of (+)-[13C]-pantoprazole is highly dependent on CYP2C19 metabolic status, but the breath test derived from it is not superior to the racemic [13C]-pantoprazole in evaluating CYP2C19 activity in vivo. Thus, racemic [13C]-pantoprazole which is relatively easy to synthesize and more stable than (+)-[13C]- pantoprazole is adequate as a probe of this enzyme.",
author = "Thacker, {David L.} and Anil Modak and Flockhart, {David A.} and Zeruesenay Desta",
year = "2013",
month = "3",
doi = "10.1088/1752-7155/7/1/016001",
language = "English",
volume = "7",
journal = "Journal of Breath Research",
issn = "1752-7155",
publisher = "IOP Publishing Ltd.",
number = "1",

}

TY - JOUR

T1 - Is (+)-[13C]-pantoprazole better than (±)-[ 13C]-pantoprazole for the breath test to evaluate CYP2C19 enzyme activity?

AU - Thacker, David L.

AU - Modak, Anil

AU - Flockhart, David A.

AU - Desta, Zeruesenay

PY - 2013/3

Y1 - 2013/3

N2 - Recently, we have shown that the (+)-[13C]-pantoprazole is more dependent on CYP2C19 metabolic status than (-)-[13C]-pantoprazole. In this study, we tested the hypothesis that (+)-[13C]-pantoprazole is a more sensitive and selective probe for evaluating CYP2C19 enzyme activity than the racemic mixture. (+)-[13C]-pantoprazole (95 mg) was administered orally in a sodium bicarbonate solution to healthy volunteers. Breath and plasma samples were collected before and up to 720 min after dosing. The 13CO2 in exhaled breath samples was measured by infrared spectrometry. Ratios of 13CO2/12CO2 after (+)-[13C]-pantoprazole relative to 13CO 2/12CO2 at baseline were expressed as delta over baseline (DOB). (+)-[13C]-pantoprazole concentrations were measured by HPLC. Genomic DNA extracted from whole blood was genotyped for CYP2C19*2, *3 and *17 using Taqman assays. Statistically significant differences in the area under the plasma concentration time curve (AUCplasma (0-∞) (p < 0.001) and oral clearance (<0.01) of (+)-[13C]-pantoprazole as well as in the breath test indices (delta over baseline, DOB30; and area under the DOB versus time curve, AUCDOB (0-120)) (p < 0.01) were observed among poor, intermediate and extensive metabolizer of CYP2C19. DOB30 and AUC DOB (0-120) adequately distinguished poor metabolizer from intermediate and extensive metabolizer of CYP2C19. Breath test indices significantly correlated with plasma elimination parameters of (+)-[ 13C]-pantoprazole (Pearson correlations: -0.68 to -0.73). Although relatively higher breath test indices were observed after administration of (+)-[13C]-pantoprazole (this study) than after (±)-[ 13C]-pantoprazole (previous study), the performance of the racemic and the enantiomer as marker of CYP2C19 activity remained similar. Our data confirm that the metabolism of (+)-[13C]-pantoprazole is highly dependent on CYP2C19 metabolic status, but the breath test derived from it is not superior to the racemic [13C]-pantoprazole in evaluating CYP2C19 activity in vivo. Thus, racemic [13C]-pantoprazole which is relatively easy to synthesize and more stable than (+)-[13C]- pantoprazole is adequate as a probe of this enzyme.

AB - Recently, we have shown that the (+)-[13C]-pantoprazole is more dependent on CYP2C19 metabolic status than (-)-[13C]-pantoprazole. In this study, we tested the hypothesis that (+)-[13C]-pantoprazole is a more sensitive and selective probe for evaluating CYP2C19 enzyme activity than the racemic mixture. (+)-[13C]-pantoprazole (95 mg) was administered orally in a sodium bicarbonate solution to healthy volunteers. Breath and plasma samples were collected before and up to 720 min after dosing. The 13CO2 in exhaled breath samples was measured by infrared spectrometry. Ratios of 13CO2/12CO2 after (+)-[13C]-pantoprazole relative to 13CO 2/12CO2 at baseline were expressed as delta over baseline (DOB). (+)-[13C]-pantoprazole concentrations were measured by HPLC. Genomic DNA extracted from whole blood was genotyped for CYP2C19*2, *3 and *17 using Taqman assays. Statistically significant differences in the area under the plasma concentration time curve (AUCplasma (0-∞) (p < 0.001) and oral clearance (<0.01) of (+)-[13C]-pantoprazole as well as in the breath test indices (delta over baseline, DOB30; and area under the DOB versus time curve, AUCDOB (0-120)) (p < 0.01) were observed among poor, intermediate and extensive metabolizer of CYP2C19. DOB30 and AUC DOB (0-120) adequately distinguished poor metabolizer from intermediate and extensive metabolizer of CYP2C19. Breath test indices significantly correlated with plasma elimination parameters of (+)-[ 13C]-pantoprazole (Pearson correlations: -0.68 to -0.73). Although relatively higher breath test indices were observed after administration of (+)-[13C]-pantoprazole (this study) than after (±)-[ 13C]-pantoprazole (previous study), the performance of the racemic and the enantiomer as marker of CYP2C19 activity remained similar. Our data confirm that the metabolism of (+)-[13C]-pantoprazole is highly dependent on CYP2C19 metabolic status, but the breath test derived from it is not superior to the racemic [13C]-pantoprazole in evaluating CYP2C19 activity in vivo. Thus, racemic [13C]-pantoprazole which is relatively easy to synthesize and more stable than (+)-[13C]- pantoprazole is adequate as a probe of this enzyme.

UR - http://www.scopus.com/inward/record.url?scp=84874873716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874873716&partnerID=8YFLogxK

U2 - 10.1088/1752-7155/7/1/016001

DO - 10.1088/1752-7155/7/1/016001

M3 - Article

VL - 7

JO - Journal of Breath Research

JF - Journal of Breath Research

SN - 1752-7155

IS - 1

M1 - 016001

ER -